

COVID-19 VACCINE OVERVIEW

Note

This overview can be used both internally and externally as educational material, as part of documents, reports, presentations etc.

The present version is update 10 and is accurate up to 21 May 2021.

Yellow highlighted text indicates changes and updates since the previous version.

Important information

Only manufacturers of the **grey highlighted** vaccines in the table have published peer-reviewed results or detailed FDA EUA documentation from Phase 3 efficacy trials.

The rest of the results are either indicative or non-peer-reviewed data from company press briefs, news stories etc. While important to understand possible efficacy levels, these 'results' are not necessarily 100% valid.

Vaccine efficacy versus effectiveness

The two terms 'efficacy' and 'effectiveness' can easily be confused. See below for a simple definition.

- Efficacy: Trial data based on perfect or near-perfect conditions measuring the relative difference in infections between a vaccinated and a placebo group.
- Effectiveness: Real-world data based on how well the vaccine work in non-controlled populations. Comparing the vaccination status of a group of confirmed cases with the vaccination status of a group that doesn't have the infection can determine the effectiveness.

Unless otherwise stated, the data in the table is from efficacy trials.

Disclaimer

This document and its content are part of correspondence with the receiving company under valid programme number. The information shared in this document is for education purposes only and shall not be considered as replacement for medical advice.

This report is written as a general guide only and the information stated therein is provided on an "as is" and "as available" basis. International SOS (hereinafter referred to as "Intl.SOS") will take reasonable care in preparing this report. However, Intl.SOS, its holding, subsidiary, group companies, affiliates, third-party content, providers or licensors and each of their respective officers, directors, employees, representatives, licensees and agents (hereinafter collectively referred to as the "Intl. with respect to this report. OS Parties") do not make any representations or warranties of any kind, express or implied, about the completeness, accuracy, authenticity, reliability, or suitability with respect to this report. Intl.SOS hereby disclaims and the receiving company hereby waives on its behalf of its holding, subsidiary, group companies, affiliates and each of their respective officers, directors, employees, representatives and agents its and their respective rights to claim against any or all of the Intl.SOS Parties for any or all liability including, without limiting the generality of the foregoing, any loss or damage to property; bodily injury or death; loss or anticipated loss of profit, loss or anticipated loss of revenue, economic loss of data, whether or not flowing directly or indirectly from the information, act or omission in question; business interruption, loss of use of equipment, loss of contract or loss of business opportunity; or indirect, special, incidental, consequential, exemplary, contingent, penal or punitive damages, howsoever arising, including out of negligence or wilful default or out of the information contained in or omitted from the report or other information which is referenced by, or linked to this report. The entire liability of Intl.SOS under or in connection with this report, whether for negligence, breach of contract, misrepresentation or otherwise is limited to the charges paid for the services of Intl.SOS for producing this report up to a maximum amounting to charges paid during the period of 1 year preceding the claim.

COVID-19 VACCINE OVERVIEW

Company/vaccine name (country)	Doses (1)	Storage temperature & shelf-life (2)	Wholesale price in US dollars	Implemented in # of countries (4)	WHO Emergency Use Listing (11)	Efficacy: preventing OLD variant ¹	Efficacy: preventing NEW variants ^{1, 4}	Lasting immunity: length and efficacy/effectiveness
Sinovac/CoronaVac® (China)	2 doses (day 0 & 14)	4°C	\$30 as of 1 December 2020 (22)	28		Brazil Phase 3 trial (5, 25): symptomatic disease 50.7% - moderate to severe disease 100% Turkey Phase 3 trial (25): symptomatic disease 84% - hospitalisation 100% Chile Phase 3 trial (25): symptomatic disease 67% - hospitalisation 85% Indonesia Phase 3 trial (25): symptomatic disease 65%	Brazil Phase 3 trial (25): might be effective against circulating P.1 variant: clinical disease 50% Chile Phase 3 trial (25): might be effective against circulating P.1 and B.1.1.7 variants: symptomatic disease 67% - hospitalisation 85%	
Beijing/Sinopharm (China)	2 doses (day 0 & 21)	4°C		47	yes	UAE, Bahrain, Egypt, Jordan Phase 3 trials expected December 2021 (7). <i>Interim results</i> from the multi-country trials suggest (26): overall 78.1% - hospitalization 78%	-	
Wuhan/Sinopharm (China)	2 doses (day 0 & 21)	4°C		2		-	-	
Bharat Biotech/Covaxin® (India)	2 doses (day 0 & 28) ⁵	2 to 8°C	\$2 in India as of 23 April 2021 (24)	5		Phase 3 trial data expected December 2022 (8)	-	
Research Institute/Qazcovid-In® (Kazakhstan)	2 doses (day 0 & 21)	-		-		Phase 3 trial data expected July 2021 (27)	-	



COVID-19 VACCINE OVERVIEW

Company/vaccine name (country)	Doses (1)	Storage temperature & shelf-life (2)	Wholesale price in US dollars	Implemented in # of countries (4)	WHO Emergency Use Listing (11)	Efficacy: preventing OLD variant ¹	Efficacy: preventing NEW variants ^{1,4}	Lasting immunity: length and efficacy/effectiveness
CanSino Biologics/Beijing Institute of Biotechnology/Convidicea® (China)	1 dose (day 0)	4°C	\$30.62 as of 16 December 2020 (23)	2		Phase 3 trial data expected July 2021 and January 2022 (28) Interim / non-published results (6): symptomatic disease 65.7% - severe disease 90.98%	-	
University of Oxford/AstraZeneca/Covishield® (UK)	2 doses (day 0 & 28-84)	4°C	\$2.15 in the EU; \$3-4 in the UK and U.S.; \$5.25 in South Africa as of 23 April 2021 (24)	150+	yes	Brazil and UK Phase 3 trials (16): overall 70.4% - symptomatic disease 60.3% (UK 2x standard doses) - symptomatic disease 90% (UK 1 low + 1 standard dose) – symptomatic disease 64.2% (Brazil 2x standard doses) US, Chile, and Peru Phase 3 trial interim analysis (21): symptomatic disease 79% - severe disease and hospitalisation 100% - efficacy among >65 80%	South Africa variant efficacy trial (19): sufficient efficacy <u>not</u> established against B.1.351 : clinical disease 10.4% - mild to moderate disease 21.9% UK variant efficacy trial non-peer reviewed (29): sufficient efficacy established against B.1.1.7 : symptomatic disease 74.6%	
Gamaleya/Sputnik V® (Russia)	2 doses (day 0 & 21)	4°C	\$10 as of 23 April 2021 (24)	39		Russia Phase 3 trial (18): symptomatic disease 92% - severe disease 100%	-	
Johnson & Johnson/Janssen Pharmaceutical (USA)	1 dose (day 0)	4°C	\$10 as of 23 April 2021 (24)	22	yes	Multi-country Phase 3 trial (9, 30): moderate to severe disease 66.9% (overall after day 14) - moderate to severe disease 66.1% (overall after day 28) - severe to critical disease 76.7% (overall after day 14) severe to critical disease 85.4% (overall after day 28)	Multi-country Phase 3 trial (31): sufficient efficacy established against B.1.351 and P.2 ⁶ : moderate to severe disease 52% (after day 14) - moderate to severe disease 64% (after day 28) severe to critical disease 73.1% (after day 14) severe to critical disease 81.7% (after day 28)	



COVID-19 VACCINE OVERVIEW

Company/vaccine name (country)	Doses (1)	Storage temperature & shelf-life (2)	Wholesale price in US dollars	Implemented in # of countries (4)	WHO Emergency Use Listing (11)	Efficacy: preventing OLD variant ¹	Efficacy: preventing NEW variants ^{1,4}	Lasting immunity: length and efficacy/ effectiveness
Curevac (Germany)	2 doses (day 0 & 21)	4°C	\$11.84 as of 20 November 2020 (38)	-		Phase 3 trial data expected April, June and September 2022 (32)	-	
Pfizer/BioNTech/Fosun/ Comirnaty® (Germany & USA)	2 doses (day 0 & 21-84)	-80 to -60°C (6 mths) -25 to -15°C (2 wks) (15)	\$19.50 for the first 100 million doses as of 23 April 2021 (24)	101	yes	<p>Argentina, Brazil, South Africa and the US Phase 3 trial (13): symptomatic disease 95%</p> <p>England effectiveness real-life study (pre-print) (34): asymptomatic and symptomatic disease 86%</p> <p>Israel effectiveness real-life study (health care workers) (33): symptomatic disease 90.5% - symptomatic disease 89-91% (during days 15-28 after first dose)</p> <p>Israel effectiveness real-life study (general population) (34): overall effectiveness 95.3% - symptomatic disease 97% - asymptomatic infection 91.5% - hospitalisation 97.2% - severe/critical hospitalisation 97.5% - deaths 96.7%</p>	<p>Israel effectiveness real-life study (general population) (34): sufficient efficacy established against B.1.1.7: overall effectiveness 95.3% - symptomatic disease 97% - asymptomatic infection 91.5% - hospitalisation 97.2% - severe/critical hospitalisation 97.5% - deaths 96.7%</p> <p>Qatar effectiveness real-life study (35): sufficient efficacy established against B.1.1.7 and B.1.351: infection with B.1.1.7 89.5% - infection with B.1.351 75% - severe, critical or fatal disease with B.1.1.7 or B.1.351 100%</p>	6-month follow up analysis non-peer reviewed (12): overall effectiveness 91.3% - severe disease 95.3/100%
Moderna (USA)	2 doses (day 0 & 28)	-20°C 4°C (1 mths)	\$25-\$37 per dose as of 23 April 2021 (24)	47	yes	The US Phase 3 trial (17): symptomatic disease 94.1% - severe and fatal disease 100%	Booster efficacy trial non-peer reviewed (10): preliminary results suggest sufficient efficacy against B1351 and P1 : no efficacy results available. The trial evaluates a booster shot based on the B1351 variant strain, a multistrain version, and the original vaccine.	6-month follow-up analysis (14): overall effectiveness 94%

COVID-19 VACCINE OVERVIEW

Company/vaccine name (country)	Doses (1)	Storage temperature & shelf-life (2)	Wholesale price in US dollars	Implemented in # of countries (4)	WHO Emergency Use Listing (11)	Efficacy: preventing OLD variant ¹	Efficacy: preventing NEW variants ^{1,4}	Lasting immunity: length and efficacy/ effectiveness
Anhui Zhifei Longcom / RBD-Dimer (ZF2001) (China)	2 or 3 doses (day 0 & 28 / 0, 28 & 56)	-		-		-	-	
FBRI ³ / EpiVacCorona / Vector Institute (Russia)	2 doses (day 0 & 21)	-		2		-	-	
Novavax (USA)	2 doses (day 0 & 21)	4°C	\$16 in the US as of 23 April 2021 (24)	-		<p>Phase 3 trial data expected January 2022 and June 2023 (36)</p> <p>England Phase 3 trial interim analysis (20): symptomatic disease 96%</p>	<p>England Phase 3 trial interim analysis (20): preliminary results suggest sufficient efficacy against B.1.1.7: symptomatic disease 86%</p> <p>South Africa Phase 1-2 trial (37): non-efficacy trial results suggest efficacy against B.1.351: symptomatic disease 51%</p>	



COVID-19 VACCINE OVERVIEW

Non-Replicating Viral Vector

Ebola vaccines use this technology.

This type of vaccine is based on a genetically modified virus that cannot replicate itself and therefore is not able to cause illness. Instead, the virus is injected with a piece of the SARS-CoV-2 virus that makes the virus produce a protein, resulting in an immune response by the body towards COVID-19.

Inactivated / killed whole virus

Polio (IPV), Influenza, Hepatitis A, Japanese Encephalitis, Rabies vaccines use this technology.

These vaccines are based on the SARS-CoV-2 virus itself, which is grown in significant amounts in laboratory settings and then killed. Vaccines based on inactivated viruses are generally not as effective as vaccines based on live virus and often require multiple injections to stimulate an adequate immune response. They are however very safe and cannot replicate in the body.

mRNA vaccines

What is injected in the body is simply the genetic instructions to make a viral protein such as the spike protein. Cells in your body then use the instructions to make the protein inside the body for your immune cells to see and respond to.

RNA vaccines are thought to initiate a strong cellular immunity and they can be produced and altered rapidly.

Protein subunit

A protein subunit vaccine only contain 'dead' parts of a pathogen, and contrary to inactivated and RNA vaccines, the protein subunit vaccine does not have any genetic material, only subunits – in this case a protein.

COVID-19 VACCINE OVERVIEW

References

1. WHO: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
2. ISGlobal: <https://www.isglobal.org/en/preguntas-frecuentes-vacuna>
3. Moderna: <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-initial-booster-data-against-sars-cov>
4. LSHTM tracker: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/
5. SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780
6. BioSpace: <https://www.biospace.com/article/comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazeneca-oxford-j-and-j-russia-s-sputnik-v/>
7. Laboratorio Elea Phoenix S.A. and Clinicaltrials.gov: <https://clinicaltrials.gov/ct2/show/NCT04560881>
8. Clinicaltrials.gov: <https://clinicaltrials.gov/ct2/show/results/NCT04641481>
9. NEJM: <https://www.nejm.org/doi/full/10.1056/NEJMoa2101544>
10. Moderna: <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-initial-booster-data-against-sars-cov>
11. WHO EUL: <https://extranet.who.int/pqweb/vaccines/covid-19-vaccines>
12. Pfizer: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious>
13. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745181/>
14. NEJM: <https://www.nejm.org/doi/10.1056/NEJMc2103916>
15. Pfizer: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data>
16. The Lancet: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32661-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext)
17. NEJM: <https://www.nejm.org/doi/full/10.1056/NEJMoa2035389>
18. The Lancet: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00234-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext)
19. NEJM: <https://www.nejm.org/doi/10.1056/NEJMoa2102214>
20. Reuters: <https://www.reuters.com/article/us-health-coronavirus-vaccines-novavax/novavax-vaccine-96-effective-against-original-coronavirus-86-vs-british-variant-in-uk-trial-idUSKBN2B32ZO>
21. BMJ: <https://www.bmj.com/content/372/bmj.n793>
22. Statista: <https://www.statista.com/chart/23658/reported-cost-per-dose-of-covid-19-vaccines/>
23. Global Times: <https://www.globaltimes.cn/content/1210093.shtml>
24. BioSpace: <https://www.biospace.com/article/comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazeneca-oxford-j-and-j-russia-s-sputnik-v/>
25. SAGE: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf
26. SAGE: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf
27. Clinicaltrials.gov: <https://www.clinicaltrials.gov/ct2/show/NCT04691908?term=NCT04691908&draw=2&rank=1>
28. Clinicaltrials.gov: <https://clinicaltrials.gov/ct2/show/results/NCT04540419?term=vaccine&cond=covid-19&draw=6> and <https://clinicaltrials.gov/ct2/show/results/NCT04526990?term=vaccine&cond=covid-19&draw=6>
29. SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160
30. US FDA: <https://www.fda.gov/media/146217/download>
31. US FDA: <https://www.fda.gov/media/146218/download>
32. Clinicaltrials.gov: <https://www.clinicaltrials.gov/ct2/show/NCT04674189?term=NCT04674189&draw=2&rank=1>, <https://clinicaltrials.gov/ct2/show/results/NCT04838847> and <https://clinicaltrials.gov/ct2/show/results/NCT04860258?term=NCT04860258&draw=2&rank=1>
33. The Lancet: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00448-7/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext)
34. The Lancet: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00947-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext)
35. The NEJM: https://www.nejm.org/doi/10.1056/NEJMc2104974?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
36. Clinicaltrials.gov: <https://clinicaltrials.gov/ct2/show/results/NCT04583995> and <https://clinicaltrials.gov/ct2/show/results/NCT04611802?term=NCT04611802&draw=2&rank=1>
37. The NEJM: <https://www.nejm.org/doi/full/10.1056/NEJMoa2103055>
38. Reuters: <https://www.reuters.com/article/us-health-coronavirus-eu-pfizer-exclusiv/exclusive-eu-could-pay-over-10-billion-for-pfizer-and-curevac-vaccines-source-idINKBN2800IC>

Foot notes

- ¹ Some data is from ongoing trials
- ² The prices listed are the wholesale price paid by countries, it is not the final prices for consumers. Prices vary between countries.
- ³ Federal Budgetary Research Institution (Russia)
- ⁴ Please refer to the International SOS Pandemic site for an overview of variants: <https://pandemic.internationalsos.com/2019-ncov/covid-19-variants>
- ⁵ There is a discrepancy between the manufacturer stated interval (28 days between doses) and the interval stated by WHO (21 days between doses). See the manufacturer statement here: <https://www.bharatbiotech.com/covaxin.html>
- ⁶ The efficacy data is higher for the P.2 lineage than for the B.1.351